Alpine Immune Sciences Initiates Trial Collaboration With Merck

by Vandana Singh, Benzinga Editor

June 30, 2021 11:17 AM | 25 seconds read | Make a Comment

Alpine Immune Sciences Inc ALPN has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc MRK.
This collaboration will evaluate the safety and efficacy of Alpine's ALPN-202 in combination with Merck's Keytruda (pembrolizumab) in patients with advanced malignancies.
Dubbed as NEON-2, the trial is currently enrolling.
Price Action: ALPN shares are down 1.93% at $8.92 during the market session on the last check Wednesday.

Posted In: Biotech News Health Care Contracts General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.